Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parametric Survival Analysis: Weibull and Exponential Methods01:14

Parametric Survival Analysis: Weibull and Exponential Methods

944
Parametric survival analysis models survival data by assuming a specific probability distribution for the time until an event occurs. The Weibull and exponential distributions are two of the most commonly used methods in this context, due to their versatility and relatively straightforward application.
Weibull Distribution
The Weibull distribution is a flexible model used in parametric survival analysis. It can handle both increasing and decreasing hazard rates, depending on its shape parameter...
944
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

337
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
337
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

4.1K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
4.1K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

1.7K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.7K
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

948
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
948
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

3.0K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
3.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Finite Element Analysis of Maxillary Overdentures Supported by Two, Three, and Four Implants.

Bioengineering (Basel, Switzerland)·2025
Same author

Multiorgan Peripheral T-Cell Lymphoma Presenting as Isolated Cardiomyopathy.

JACC. Case reports·2025
Same author

Population Pharmacokinetics and Exposure-Response Model-Based Bayesian Extrapolation of FVC-Based Efficacy Endpoints From Adults to Pediatric Patients Receiving Nintedanib.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Mitochondrial respiratory activity and DNA damage in peripheral blood mononuclear cells in borderline personality disorder.

Psychological medicine·2025
Same author

Exposure-Efficacy Meta-Model of Nintedanib in Adult Patients With Chronic Fibrosing Interstitial Lung Diseases.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Lipid Monolayers Adsorbing mRNA as Models for mRNA Enclosed in Lipid Nanoparticles for Transfection.

Langmuir : the ACS journal of surfaces and colloids·2025

Related Experiment Video

Updated: Dec 31, 2025

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

816

Parametric Time-to-Event Model for Acute Exacerbations in Idiopathic Pulmonary Fibrosis.

Fei Tang1,2, Benjamin Weber1, Susanne Stowasser3

  • 1Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.

CPT: Pharmacometrics & Systems Pharmacology
|January 11, 2020
PubMed
Summary

Idiopathic pulmonary fibrosis (IPF) exacerbation risk can be predicted using a new parametric model. Key factors include lung function decline, oxygen use, and age, aiding in early identification of high-risk patients.

More Related Videos

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

1.5K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.9K

Related Experiment Videos

Last Updated: Dec 31, 2025

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

816
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
06:03

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

1.5K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

10.9K

Area of Science:

  • Pulmonology
  • Medical Statistics
  • Pharmacology

Background:

  • Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease characterized by exacerbations.
  • Predicting IPF exacerbations is crucial for patient management and clinical trial design.
  • Nintedanib is a tyrosine-kinase inhibitor studied for IPF treatment.

Purpose of the Study:

  • To develop and validate a parametric time-to-event model for IPF exacerbations.
  • To identify key predictors of exacerbation risk in IPF patients.
  • To inform patient stratification and accelerate novel treatment development.

Main Methods:

  • Parametric survival analysis was applied to time-to-first exacerbation data from the INPULSIS-1/2 phase III trials.
  • Univariate and multivariate analyses, including stepwise covariate modeling, were used to identify significant predictors.
  • Data from 1,061 subjects with 63 exacerbation events were analyzed.

Main Results:

  • Several baseline and longitudinal factors were significant predictors of exacerbation risk.
  • Key predictors identified in the final model include decline in forced vital capacity (FVC) to week 52, baseline percent-predicted FVC (%pFVC), supplemental oxygen use, and age.
  • These factors collectively contribute to predicting the risk of IPF exacerbations.

Conclusions:

  • A robust parametric model can identify patients at high risk of IPF exacerbations.
  • The identified predictors offer valuable insights for clinical decision-making and patient monitoring.
  • This model can potentially accelerate the development and testing of new therapies for IPF.